Organisation · Unternehmen
Eli Lilly and Company
eli-lilly-and-company-eutr-14339939
Aussagen (8)
eu transparency category
Companies & groups
dokumentiert
[Q-8266]
eu transparency goals
Lilly is a leading innovative biopharmaceutical company that unites caring with discovery to make life better for people around the world. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Headquartered in the US, Lilly has approximately 46,913 employees worldwide. In 2024 global revenue was approx. $45.04 billion, of which 24.4% as a percentage of sales was invested in Research and Development. Average cost to discover and develop a new drug: $2.6 billion. Average length of time from discovery to patient: 10 years. This data will be updated as soon as new annual report is available ( approx. April 2026)
( https://investor.lilly.com/financials.cfm )
Headquartered in the US, Lilly has approximately 46,913 employees worldwide. In 2024 global revenue was approx. $45.04 billion, of which 24.4% as a percentage of sales was invested in Research and Development. Average cost to discover and develop a new drug: $2.6 billion. Average length of time from discovery to patient: 10 years. This data will be updated as soon as new annual report is available ( approx. April 2026)
( https://investor.lilly.com/financials.cfm )
dokumentiert
[Q-8266]
eu transparency id
04657143399-39
dokumentiert
[Q-7535]
headquarters city
Indianapolis
dokumentiert
[Q-8266]
headquarters country
GB
dokumentiert
[Q-8266]
interest class
business_company
dokumentiert
[Q-29773]
legal form
Corporation
dokumentiert
[Q-8266]
legal form class
ausland_sonstig
berichtet
[Q-29773]